On Apr. 2, 2020, Incyte announced it was working with the U.S. Food and Drug Administration (FDA) to initiate a phase 3 clinical trial (RUXCOVID) to evaluate the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm. The collaborative study was sponsored by Incyte in the U.S. and Novartis outside of the U.S.